Log in

NASDAQ:NBRVNabriva Therapeutics Stock Price, Forecast & News

$0.79
+0.04 (+5.31 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.75
Now: $0.79
$0.80
50-Day Range
$0.50
MA: $0.64
$1.14
52-Week Range
$0.49
Now: $0.79
$2.77
Volume15.23 million shs
Average Volume6.83 million shs
Market Capitalization$750.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Read More
Nabriva Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NBRV
CUSIPN/A
Phone353-1649-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.48 million
Book Value$0.04 per share

Profitability

Net Income$-82,760,000.00
Net Margins-1,001.59%

Miscellaneous

Employees162
Market Cap$750.36 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

How has Nabriva Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBRV shares have decreased by 34.5% and is now trading at $0.7930. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nabriva Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Nabriva Therapeutics.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nabriva Therapeutics.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The biotechnology company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.39 million. Nabriva Therapeutics had a negative net margin of 1,001.59% and a negative return on equity of 238.67%. View Nabriva Therapeutics' earnings history.

What price target have analysts set for NBRV?

6 brokerages have issued 1 year price objectives for Nabriva Therapeutics' shares. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' stock price to reach $3.92 in the next year. This suggests a possible upside of 393.9% from the stock's current price. View analysts' price targets for Nabriva Therapeutics.

Has Nabriva Therapeutics been receiving favorable news coverage?

News coverage about NBRV stock has trended positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nabriva Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutNabriva Therapeutics.

Who are some of Nabriva Therapeutics' key competitors?

What other stocks do shareholders of Nabriva Therapeutics own?

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:
  • Mr. Theodore R. Schroeder, CEO & Director (Age 65, Pay $707.62k)
  • Mr. Steven P. Gelone, Pres & COO (Age 52, Pay $667.5k)
  • Dr. Colin Broom, Director (Age 64, Pay $39.13k)
  • Dr. Jennifer Schranz M.D., Chief Medical Officer (Age 55, Pay $620.85k)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 58)

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (0.18%), Rock Springs Capital Management LP (0.11%), Sabby Management LLC (0.04%), Morgan Stanley (0.04%), Wells Fargo & Company MN (0.01%) and Exane Derivatives (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Steven P Gelone and Theodore R Schroeder. View institutional ownership trends for Nabriva Therapeutics.

Which major investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Sabby Management LLC, and Morgan Stanley. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender, and Steven P Gelone. View insider buying and selling activity for Nabriva Therapeutics.

Which major investors are buying Nabriva Therapeutics stock?

NBRV stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Exane Derivatives, and Wells Fargo & Company MN. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Jennifer Schranz, and Theodore R Schroeder. View insider buying and selling activity for Nabriva Therapeutics.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $0.79.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $750.36 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is www.nabriva.com.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.